BR112012031451A2 - cloreto de glicopirrônio treo cristalino, processo para preparar cloreto de glicopirrônio treo cristalino, composição farmacêutica e uso de cloreto de glicopirrônio treo cristalino - Google Patents

cloreto de glicopirrônio treo cristalino, processo para preparar cloreto de glicopirrônio treo cristalino, composição farmacêutica e uso de cloreto de glicopirrônio treo cristalino

Info

Publication number
BR112012031451A2
BR112012031451A2 BR112012031451A BR112012031451A BR112012031451A2 BR 112012031451 A2 BR112012031451 A2 BR 112012031451A2 BR 112012031451 A BR112012031451 A BR 112012031451A BR 112012031451 A BR112012031451 A BR 112012031451A BR 112012031451 A2 BR112012031451 A2 BR 112012031451A2
Authority
BR
Brazil
Prior art keywords
treo
crystalline
glycopyrronium chloride
glycopyrronium
chloride
Prior art date
Application number
BR112012031451A
Other languages
English (en)
Inventor
Enrico Vigano
Ernesto Landonio
Fausto Pivetti
Monica Bocchi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of BR112012031451A2 publication Critical patent/BR112012031451A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112012031451A 2010-06-14 2011-06-13 cloreto de glicopirrônio treo cristalino, processo para preparar cloreto de glicopirrônio treo cristalino, composição farmacêutica e uso de cloreto de glicopirrônio treo cristalino BR112012031451A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10165786 2010-06-14
PCT/EP2011/002893 WO2011157387A1 (en) 2010-06-14 2011-06-13 Crystal form of glycopyrronium chloride

Publications (1)

Publication Number Publication Date
BR112012031451A2 true BR112012031451A2 (pt) 2016-12-06

Family

ID=42751657

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012031451A BR112012031451A2 (pt) 2010-06-14 2011-06-13 cloreto de glicopirrônio treo cristalino, processo para preparar cloreto de glicopirrônio treo cristalino, composição farmacêutica e uso de cloreto de glicopirrônio treo cristalino

Country Status (11)

Country Link
US (1) US9174937B2 (pt)
EP (1) EP2580195B1 (pt)
KR (1) KR101736529B1 (pt)
CN (1) CN102939280B (pt)
AR (1) AR081889A1 (pt)
BR (1) BR112012031451A2 (pt)
CA (1) CA2802584C (pt)
ES (1) ES2528957T3 (pt)
HK (1) HK1177200A1 (pt)
RU (1) RU2569852C2 (pt)
WO (1) WO2011157387A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699257T3 (es) * 2013-02-28 2019-02-08 Dermira Inc Sales de glicopirrolato
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
RS65452B1 (sr) 2013-10-22 2024-05-31 Chiesi Farm Spa Postupak za pripremu pde4 inhibitora
US9926270B2 (en) 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
PT937041E (pt) * 1996-11-11 2003-09-30 Christian R Noe Utilizacao de um sal farmaceuticamente aceitavel de (3r,2'r)-3-¬(ciclopentil-hidroxifenilacetil)oxi|-1,1-dimetil-pirrolidinio para a preparacao de um medicamento
AT412088B (de) * 2002-12-18 2004-09-27 Pharmacon Forschung & Beratung Gmbh Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere
WO2005082413A2 (en) * 2004-02-27 2005-09-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0504463D0 (en) * 2005-03-03 2005-04-13 Arakis Ltd Method of crystallisation and purification
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
CN102388021B (zh) * 2009-04-09 2015-02-18 诺华股份有限公司 吡咯烷鎓盐的制备方法

Also Published As

Publication number Publication date
KR101736529B1 (ko) 2017-05-17
HK1177200A1 (en) 2013-08-16
CA2802584C (en) 2018-08-21
ES2528957T3 (es) 2015-02-13
EP2580195A1 (en) 2013-04-17
CN102939280A (zh) 2013-02-20
CA2802584A1 (en) 2011-12-22
EP2580195B1 (en) 2014-12-03
RU2569852C2 (ru) 2015-11-27
KR20130119844A (ko) 2013-11-01
US20110305645A1 (en) 2011-12-15
US9174937B2 (en) 2015-11-03
RU2012154006A (ru) 2014-07-20
WO2011157387A1 (en) 2011-12-22
AR081889A1 (es) 2012-10-24
CN102939280B (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
BRPI1006794A2 (pt) Processo para preparar inibidores jak e compostos intermediários relacionados
BR112014010460A2 (pt) composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BR112014001418A2 (pt) compostos, processo para a preparação dos compostos, e, uso dos compostos
BR112013014044A2 (pt) composição, produto alimentício e processo para prepará-lo
BR112012029929A2 (pt) processo para preparar um produto de carga mineral tratada, produto de carga mineral tratada, uso de um produto de carga mineral tratada, e, material de película
BR112012018829A2 (pt) processo para preparar carboximetil celulose, carboximetil celulose e uso de carboximetil celulose
BR112012026843A2 (pt) composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
BR112013028959A2 (pt) composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BRPI0921399A2 (pt) composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante
BR112012029906A2 (pt) produto de carga mineral tratada, processo para preparar um produto de carga mineral tratada, uso de um produto de carga mineral tratada, e, material de película
BRPI0822946A2 (pt) Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida
BR112013030832A2 (pt) processo para tratar as fibras queratínicas e uso de uma composição
BR112013016365A2 (pt) composição de lipossoma e processo para produção do mesmo
BR112014009684A2 (pt) processo para preparar polímeros, polímero e uso de polímeros
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BR112012021476A2 (pt) composto, processo para preparação do composto, composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz do composto e emprego de tal composto
BR112014026564A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
BRPI1008277A2 (pt) composição de cloreto de sódio, processo para a preparação de uma composição de cloreto de sódio e uso de uma composição de cloreto de sódio não aglomerante
BR112014026565A2 (pt) formulação, uso de uma formulação, e, processo para produzir uma formulação
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
BR112012029225A2 (pt) processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral
BR112012002087A2 (pt) Grânulos, processo para a preparação dos grânulos e uso dos grânulos
BR112012031451A2 (pt) cloreto de glicopirrônio treo cristalino, processo para preparar cloreto de glicopirrônio treo cristalino, composição farmacêutica e uso de cloreto de glicopirrônio treo cristalino
BR112013005986A2 (pt) processo para preparar uma composição derivada de estolídeo e composição derivada de estolídeo
BR112012029824A2 (pt) métodos para o preparo de cloreto de glicopirrônio, cloreto de glicopirrônio, composição farmacêutica e uso de cloreto de glicopirrônio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]